 |
Prospector
Profile
3-24-003
|
| |
| Anadys Pharmaceuticals, Inc. |
NAICS |
541710 |
| 3115 Merryfield Row,
San Diego, CA 92121 |
Description |
Biotechnology |
| (858) 530-3600 |
Employees |
49 |
| http://www.anadyspharma.com/ |
Revenue |
(mil) |
24.1200 |
| |
Income |
(mil) |
-9.1700 |
| |
Assets |
(mil) |
61.5300 |
| |
Liability |
(mil) |
5.8500 |
| |
(for the year ended 2007-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Anadys Pharmaceuticals, Inc., had a net loss of $9.17 million for the year ended December 31, 2007, much lower than the net losses of $26.76 million and $21.92 million reported during the years ended December 31, 2006 and 2005, respectively. The decrease in net loss is due primarily to increased revenues from collaborative agreements of $24.12 million for fiscal year 2007, compared to revenues of $5.42 million and $4.89 million in 2006 and 2005, respectively. The Company's balance sheet at December 31, 2007, showed an accumulated deficit of $223.65 and stockholders' equity of $55.68 million.
|
| |
|
Intellectual Property:
As of December 31, 2007, Anadys Pharmaceuticals had one non-U.S. patent issued related to the NS5B hepatitis C drug discovery and drug development program and one non-U.S. patent issued related to the ANA773 drug discovery and drug development program. It also has numerous patent applications pending in the U.S. and in foreign countries relating to these programs. In addition, the Company's patent portfolio contains a number of issued patents and pending patent applications relating to its discovery technologies and currently inactive programs. [SEC Filing 10-K 03-05-08]
|
| |
|
Description:
Anadys Pharmaceuticals, Inc., engages in discovery, development, and commercialization of small molecule medicines for the treatment of viral diseases and cancer.
|
| |
|
Officers:
Steve Worland, Ph.D. (Pres., CEO & Dir.); James T. Glover (SVP & CFO); James L. Freddo, M.D. (Chief Medical Officer); Mary Yaroshevsky-Glanville (VP); Elizabeth E. Reed, J.D. (VP & Sec.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol ANDS; NasdaqGM;
28,651,106 common shares outstanding as of August 1, 2007.
|
| |
| |
| |
| return to main page |
|
|
